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A B S T R A C T
Equivocal HER2 status has been variably defined in the past, and its clinical implications have long been debated.
In the 2018 focused update, ASCO/CAP guidelines recommended that tumours with double-equivocal (by
immunohistochemistry and in situ hybridization assays) HER2 status should be considered HER2-negative due
to the lack of evidence for any benefit of HER2-targeted therapy.
The biology and the response to systemic therapies of tumours co-expressing HR and HER2 is quite complex.
There is an extensive bi-directional cross-talk between these 2 pathways, that may result in both intrinsic and
acquired resistance to endocrine agents, as well as in lower sensitivity to HER2-targeted therapies. In fact, neo-
adjuvant studies indicate that pCR rates are significantly lower in HER2-positive/ER-positive than ER-negative
tumours, regardless the type of HER2 targeted treatment.
The recent identification of different subtypes of HER2-positive breast cancer, according to the co-expression of
HR and/or the molecular (intrinsic) subtyping, has prompted a renewed interest for clinical studies aimed at
better tailoring the systemic therapy for these patients. A subgroup of them might not need chemotherapy if
treated with dual HER2 blockade, and this option has been tested in a number of neo-adjuvant trials.
In addition, triple targeting of HR, HER2, and CDK4/6 pathways simultaneously may be an effective treatment
and overcome the drug resistance mechanisms that are typical of the disease.
Finally, HER2-positive breast cancer may well benefit from immunotherapeutic interventions with anti-
programmed cell death protein 1 (PD-1) and programmed cell death ligand 1 (PD-L1) agents.
© 2019 Elsevier Ltd. All rights reserved.
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Highlights
• Patients with equivocal HER2 status do not benefit from HER2-
targeted therapy
• pCR rates after neoadjuvant chemotherapy are lower in HER2-
positive/ER-positive tumours
• Triple targeting of HR, HER2, and CDK4/6 or PD-1/PD-L1 may be
an effective therapeutic strategy
The challenges of equivocal HER2 status
Expression and amplification of the HER2 gene in breast carcinoma
are continuous variables, making it arbitrary to define precise
thresholds for positive and negative results. Accordingly, for both
immunohistochemical (IHC) and in situ hybridization (ISH) assayswe
have been forced to accept a grey zone of equivocal results between
those that are frankly positive and frankly negative.
In the IHC assays, equivocal results are characterised by a weak
to moderate circumferential membrane staining observed in more
than 10% invasive tumour cells. Less common equivocal patterns of
staining include an intense but incomplete membrane staining in
more than 10% invasive tumour cells (most often encountered in
invasive micropapillary carcinomas), and an intense circumferential
membrane staining in 10% or less tumour cells. An equivocal IHC
result requires reflex testing of the same sample with ISH assays, to
assess whether or not the HER2 gene is amplified [1].
In the ISH assays, equivocal results have been variably defined in
the past, according to a ratio (between the mean gene copy number
and the chromosome enumeration probe 17) of 1.8 to 2.2, or to a
mean gene copy number of 4 to <6 in tumours with a ratio of <2 [2,3].
The clinical implications of “double-equivocal” (i.e.: with equivocal
results both in IHC and ISH assays) HER2 status of breast carcinomas
have long been debated and have challenged oncologists and patients
due to a perceived ambivalence about whether to recommend HER2-
targeted therapy. In 2013, the ASCO/CAP guideline recommendations
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suggested that oncologists might consider HER2-targeted therapy in
such cases on the basis of patient status (comorbidities, prognosis,
and so on) and patient preferences, after discussing available clinical
evidence [3]. In the 2018 focused update of the same guidelines,
however, it is now recommended that these cases be considered
HER2-negative (without additional testing on the same specimen),
due to the lack of evidence for any benefit from HER2-targeted
therapy. Clinical correlation with other factors in a particular case
(such as grade and special histologic subtypes) or repeat testing of
other tissue samples (of the primary tumours or lymph node
metastasis if present) from the patient may also be appropriate in
this setting. In particularly challenging cases or if the results are in
question, expert consultation may be appropriate and may include
alternative probes or other molecular testing [1]. The vast majority of
these double-equivocal tumours have lowabundance of HER2mRNA
and aremolecularly classified as luminal subtypes (discussed below).
Intratumoral heterogeneity of HER2-positive breast carcinomas
HER2-positive breast cancer is defined as a tumour overexpressing
the HER2 protein (with an immunohistochemical score of 3+) and/or
showing gene amplification (with a ratio between the mean gene
copy number and the chromosome enumeration probe 17 of ≥2, or a
mean gene copy number of ≥6) [1].
Though the vast majority of HER2-positive breast cancers exhibit
overexpression of the protein and/or gene amplification in almost all
the neoplastic cells, still a number of cases show intratumoral
heterogeneity, with an intermingling of positive and negative
populations of invasive tumour cells. Sometimes, the heterogeneity
correlates with, and it may be predicted by, a morphological
heterogeneity of the tumour, like in case of mixed histologies (e.g.:
ductal and lobular) or of tumour areas with different histological
grades. More often, however, there are no identifiable morphological
differences between the HER2-positive and the HER2-negative
components. The current guidelines recommend that tumours are
considered HER2-positive when more than 10% of the invasive
neoplastic cells show overexpression or amplification of the HER2
gene. These features, however, should be observed within a
homogeneous and contiguouspopulationof invasive tumourcells [1].
Co-expression of hormone receptors in HER2-positive tumours
The prototypical features of HER2-positive breast carcinomas include
lack of hormone receptor (HR) expression, ductal histotype,moderate
to high tumour grade, and high Ki67 labelling index [4,5]. Actually,
however, 60% or more of HER2-positive breast cancers co-express
estrogen receptors (ER) and 40% to 50% of them also express
progesterone receptors (PgR), being often referred to as “triple-
positive” breast cancer [6,7]. Co-expression of HRmay be observed in
tumours with morphologically different cell populations (e.g.: mixed
ductal and lobular carcinomas, or tumours with high- and low-grade
components), where the ductal and/or the high-grade component is
more likely to be HER2-positive, and the other component HR-
positive and HER2-negative. In most instances, however, expression
of HR togetherwith over-expression and/or amplification of HER2 are
exhibited by the very same tumour cells. In the majority of these
cases, the neoplastic population is homogeneously positive for HER2,
and the co-expression of HR is restricted to a subset of the tumour
cells. In particular, ER immunoreactivity is more often encountered in
a lower percentage of cells, and the staining intensity is weaker, than
in HER2-negative tumours. PgR immunoreactivity may overlap
ER expression, or be lower or absent [6]. Less commonly, tumours
may show HER2 overexpression/amplification and ER immunoreac-
tivity (with or without PgR) in the vast majority -if not all- the
neoplastic cells.
Molecular classification of HER2-positive breast cancer
The technology of gene expression profiling has unveiled the striking
molecular heterogeneity of breast carcinomas, and has paved theway
for a new classification of these tumours, based on their molecular
characteristics (intrinsic subtypes). Four major molecular classes
(Luminal A, Luminal B, HER2-enriched and Basal-like) have been
identified, and the prognostic value of this classification has been
repeatedly confirmed [8,9]. The molecular classes do partially
overlap, but do not coincide with, those defined by immunohisto-
chemical surrogates (ER, PgR, Ki67 and HER2). This holds also true for
tumours that are clinically HER2-positive, based on IHC and ISH
assays. When subjected to gene expression profiling, only approxi-
mately half of these tumours belong to the HER2-enriched class,
while the remaining cluster with the Luminal A and B, or the Basal-
like subtypes [10].
It is tempting to speculate that the molecularly HER2-enriched
tumours are those clinically HER2-positive but HR-negative, whereas
the tumours that co-express HR would correspond to those that are
molecularly classified as Luminal. Unfortunately, however, this
assumption has not been confirmed by studies comparing intrinsic
subtypes and the IHC surrogates. Indeed, a fraction (10% to 18%) of
tumours that are clinically HER2-positive and HR-negative belong to
the Luminal intrinsic subtype, and 43% to 54% of tumours co-
expressing HR belong to the HER2-enriched subtype when tested
with the PAM50 assay [10–13].
We also have compared the clinical and molecular classification of
5788 tumour samples of patients enrolled in theMINDACT trial using
an alternative multigene expression panel (TargetPrint, Agendia, The
Netherlands). Of the 429 clinically HER2-positive and ER-positive
samples, 216 (50.3%) were classified as HER2-enriched by the
molecular assay [14].
Biological and clinical implications of hormone receptor co-
expression and of intrinsic subtyping
HER2-positive breast cancers that do not co-express HR, mostly
belonging to the HER2-enriched intrinsic subtype, are driven by the
activation of the HER2 pathway (HER2 addiction), and are exquisitely
sensitive to HER2-targeted therapies.
On the other hand, the biology and the response to systemic
therapies of tumours co-expressing HR is much more complex. They
may be oncogenically driven by either or both the HR and the HER2
signalling pathways, in a similar manner as for a hybrid car with two
different engines. There is an extensive bi-directional cross-talk
between these two pathways, that may result in both intrinsic and
acquired resistance to endocrine agents, as well as in lower
sensitivity to HER2-targeted therapies. There is plenty of evidence
from neo-adjuvant studies that pCR rates are significantly lower in
ER-positive than ER-negative tumours, regardless the type of HER2-
targeted treatment [7], either trastuzumab alone or the dual
blockade with trastuzumab and pertuzumab [15] or with trastuzu-
mab and lapatinib [16].
Moreover, the pooled analysis of the German neo-adjuvant studies
suggests that pCR may be a suitable surrogate endpoint for HER2-
positive/HR-negative but not for HER2-positive/HR-positive breast
cancer patients [17].
In the adjuvant setting, however, a significant interaction between
HR status (or intrinsic subtypes) and the treatment effect of single
agent trastuzumab or of dual HER2 blockade (trastuzumab plus
lapatinib or pertuzumab) has not been documented. At variancewith
the neo-adjuvant setting, patients enrolled in adjuvant trials have
also received endocrine treatment, and the prevalent mechanism(s)
of action of HER2-targeted agents may be different in the two
settings. Nevertheless, there are some limitations in the studies, such
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as the simplistic definition of HR status (positive vs. negative), which
does not take into account the extent of HRexpression, and the lack of
centralized evaluation.
In a retrospective evaluation of records from more than 3000
patients enrolled in the HERA trial, however, we reported for the first
time a significant association between ER-positive tumours with
lower levels of HER2 gene amplification and lessmagnitude of benefit
to adjuvant trastuzumab [18].
Recently, in the post-neoadjuvant setting, results from the
KATHERINE trial indicate that among patients with HER2-positive
early breast cancer who had residual invasive disease after
completion of neoadjuvant therapy, the risk of recurrence of invasive
breast cancer or deathwas 50% lowerwith adjuvant T-DM1 thanwith
trastuzumab alone, irrespective of HR status [19].
Prior to this, however, the ExeNET trial showed that 1 year of
neratinib (an irreversible pan-HER tyrosine kinase inhibitor) after
chemotherapy and trastuzumab adjuvant therapy signiﬁcantly
reduces the likelihood of clinically relevant breast cancer relapse
[20]. Neratinib seemed to have a greater effect in patients with HR-
positive breast cancer (most of whom were receiving concurrent
hormone therapy) than in thosewith HR-negative disease. In amodel
of HER2-positive/ER-positive xenografts after tumour regrowth
following treatment with trastuzumab and paclitaxel, mirroring the
ExteNET population, treatment with neratinib and fulvestrant,
compared with fulvestrant alone, showed prolonged complete
responses in vivo and preserved sensitivity to endocrine therapy
after recurrence [21]. This observation suggests an absence of cross-
resistance between trastuzumab and neratinib in the hormone
receptor-positive population [20].
New treatment options for patients with HER2-positive
disease
The identification of different subtypes of HER2-positive breast
cancer, according to the co-expression of HR and/or the intrinsic
subtyping, has prompted a renewed interest for clinical studies aimed
at better tailoring the systemic therapy of the affected patients.
It has been mentioned already that the exquisite sensitivity of
HER2-addicted tumours to targeted therapies suggests that a
subgroup of patients with early-stage HER2-positive breast cancer,
mostly those with the HER2-enriched subtype, might not need
chemotherapy if treated with dual HER2 blockade. This option has
been tested in a number of neo-adjuvant trials, where the
combination of trastuzumab and lapatinib or pertuzumab without
cytotoxic therapy has achieved remarkable pCR rates of approxi-
mately 20–30% [12,15,22–25].
Neo-adjuvant regimens without use of systemic chemotherapy
have also been exploited for HER2-positive/HR-positive disease. In
the ADAPT HER2-positive/HR-positive trial, neo-adjuvant T-DM1
(with or without endocrine therapy) given for only 12 weeks
achieved a meaningful pCR rate, thus sparing a substantial number
of patients the adverse effects of systemic chemotherapy [26].
HER2-positive/HR-positive (or Luminal) tumours, however, rep-
resent a major therapeutic challenge because they harbour
multiple oncogenic drivers and pathways of therapeutic resistance.
The concomitant block of the HR pathway together with an
effective block of homo- and hetero-dimer signalling of HER2 by
trastuzumab and lapatinib or pertuzumab without addition of
systemic chemotherapy has been tested in the neo-adjuvant and in
the metastatic settings. The neoadjuvant TBCRC006 trial tested
the hypothesis, and showed a relatively high rate (21%) of pCR in
breast with the combination of lapatinib, trastuzumab and
letrozole [23]. In the phase II PerELISA trial, patients with HER2-
positive/HR-positive operable breast cancer received 2-weeks
letrozole. Then patients classified as molecular responders (Ki67
relative reduction after 2 weeks >20% from baseline) continued
letrozole and started trastuzumab and pertuzumab for 5 cycles
achieving pCR in 20.6% of the cases. pCR rate, however, was
significantly higher in HER2-enriched vs. other subtypes (45.5% vs.
13.8%) according to PAM50 [24].
In the PAMELA trial, investigating the role of lapatinib and
trastuzumab without chemotherapy, the pCR rate (breast only) in
the cohort of hormone receptor positive/HER2-enriched after
endocrine therapy plus dual HER2 blockade was 32% [12].
In themetastatic setting, dual block of HER2with trastuzumab and
pertuzumab combined with an aromatase inhibitor in the PERTAIN
study led to a significant 3-months longer PFS than observed with
trastuzumab and aromatase inhibitor [27]. These trials indicated that
dual targeting of HER2 is superior to single block in interfering with
the cross-talk between HR and HER2.
ER and HER2 signalling pathways exert a synergistic effect on
the cell cycle checkpoints, and there are multiple feedback loops
between these pathways. It is therefore attractive to investigate the
combination of CDK4/6 inhibitors with HER2-targeted agents and
endocrine interventions for the treatment of HER2-positive/
HR-positive disease. Triple targeting of HR, HER2, and CDK4/6
pathways simultaneously may be an effective treatment and
overcome the drug resistance mechanisms that are typical of the
disease. Furthermore, the combination is safe, with a favourable
toxicity profile and non-overlapping side effects.
This therapeutic strategy has been successfully exploited in
the neo-adjuvant setting [28] and in the advanced setting [29],
and additional clinical trials testing the triple blockade of
ER, HER2 and CDK4/6 in locally advanced and metastatic HER2-
positive/HR-positive breast cancer are currently recruiting
patients (ClinicalTrials.gov identifier NCT03054363, NCT02947685,
NCT02448420, NCT02675231 and NCT02657343).
An overlapping mechanism of resistance to all three drugs
probably exists (cyclin E overexpression) [30,31]. The assessment of
this and other potential resistancemechanisms should be performed
in the ongoing clinical trials testing triple combinations of anti-
hormonal therapy with HER2 and CDK4/6-targeted agents.
Based on non-overlapping resistance mechanisms, other possible
combined therapies for the treatment of HR-positive and HER2-
positive breast cancer may be exploited (for example, a combination
of anti-hormonal drugs with HER2-targeted agents and PI3 K or
mTOR inhibitors). Some of these combinations are now being tested
in a clinical trial in the metastatic setting (ClinicalTrials.gov identifier
NCT03767335).
Finally, HER2-positive breast cancer may well benefit from
immunotherapeutic interventions with anti-programmed cell
death protein 1 (PD-1) and programmed cell death ligand 1 (PD-L1)
agents. Indeed, these tumours may have substantial amounts
of tumour infiltrating lymphocytes (TILs) that are associated with
the likelihood of achieving a pathological complete response
and having improved survival [32]. Preclinical studies have already
suggested that the combination of trastuzumab with drugs
targeting immune checkpoints could overcome trastuzumab resist-
ance [33].
High expression of PD-1 and PD-L1, and other checkpoint
molecules has been observed in immune cells of HER2-positive
breast cancer [34].We have already shown that the combination of an
anti-PD-1 drug (pembrolizumab) and trastuzumab was safe and
showed activity and durable clinical benefit in patients with PD-L1-
positive, trastuzumab-resistant, advanced, HER2-positive breast
cancer [35]. A regimen including dual targeting of HER2 with
trastuzumab and pertuzumab and an anti-check point (atezolizumab
or pembrolizumab) agent is currently being tested in the neo-
adjuvant setting (APTneo trial, ClinicalTrials.gov identifier
NCT03125928 and neoHIP trial NCT03747120).
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Epilogue
HER2-positive breast cancer is a biologically and clinically heteroge-
neous disease, as documented by pathology-based assessment of HR
and HER2 status, and by the intrinsic subtyping derived from gene
expression profiles. HER2-enriched tumours (most of which do not
co-express hormone receptors) are exquisitely sensitive to HER2-
targeted agents, to the point that at least some patients may be cured
by dual HER2 blockade only, without systemic chemotherapy.
Tumours co-expressing HR (most of which belong to the luminal
intrinsic subtypes), however, are relatively resistant to both endo-
crine interventions and HER2-targeted therapies, thus requiring a
combination therapy aimed at blocking both signalling pathways.
Addition of CDK4/6 inhibitors to endocrine and HER2-targeted
treatments has recently shownpromising results in the neo-adjuvant
setting, and it is currently being tested in a numberof ongoing clinical
trials. Finally, there is initial evidence in the advanced setting that
HER2-positive breast cancer may benefit from the combination of
HER2-targeted agents and immunotherapy with anti-PD-1 or PD-L1
agents, and this therapeutic strategy is also being investigated in the
neo-adjuvant setting.
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